RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2003; 23(2): 215-224
DOI: 10.1055/s-2003-41134
DOI: 10.1055/s-2003-41134
Paraneoplastic Neurologic Syndromes: Approaches to Diagnosis and Treatment
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
01. August 2003 (online)
ABSTRACT
There is increasing evidence that many paraneoplastic neurologic syndromes are immune-mediated. Because symptoms usually have an acute onset and precede the tumor diagnosis, the recognition of a neurologic disorder as a paraneoplastic syndrome is challenging. The poor response to treatment of many paraneoplastic neurologic syndromes has been attributed to the early, irreversible pathological changes involving the nervous system. This may account for the more frequent responses to therapy of some paraneoplastic neurologic syndromes affecting the peripheral nerves and neuromuscular junction compared with those that produce neuronal degeneration. This review focuses on the current therapeutic approaches to immune-mediated paraneoplastic neurologic syndromes, including prompt recognition of the disorder, detection and treatment of the associated tumor, and, in some disorders, immunosuppressive therapy.
KEYWORDS
Paraneoplastic neurologic syndromes
REFERENCES
- 1 Dalmau J, Posner J B. Paraneoplastic syndromes affecting the nervous system. Semin Oncol . 1997; 24 318-328
- 2 Rudnicki S A, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve and muscle. Muscle Nerve . 2000; 23 1800-1818
- 3 Rosenfeld M R, Dalmau J. The clinical spectrum and pathogenesis of paraneoplastic disorders of the central nervous system. Hematol Oncol Clin North Am . 2001; 15 1109-1128
- 4 Dropcho E J. Remote neurologic manifestations of cancer. Neurol Clin . 2002; 20 85-122
- 5 Dalmau J, Gultekin H S, Posner J B. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol . 1999; 9 275-284
- 6 Albert M L, Darnell J C, Bender A, Francisco L M, Bhardwaj N, Darnell R B. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med . 1998; 11 1321-1324
- 7 Tanaka M, Tanaka K, Shinozawa K, Idezuka J, Tsuji S. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci . 1998; 161 88-90
- 8 Tanaka K, Tanaka M, Inuzuka T, Nakano R, Tsuji S. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J Neurol Sci . 1999; 163 159-162
- 9 Graus F, Dalmau J, Rene R. et al . Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol . 1997; 15 2866-2872
- 10 Maddison P, Newsom-Davis J, Mills K R, Souhami R L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet . 1999; 353 117-118
- 11 Rojas I, Graus F, Keime-Guibert F. et al . Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology . 2000; 55 713-715
- 12 Vincent A. Antibodies to ion channels in paraneoplastic disorders. Brain Pathol . 1999; 9 285-291
- 13 Tanaka K, Tanaka M, Onodera O, Igarashi S, Miyatake T, Tsuji S. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci . 1994; 127 153-158
- 14 Tanaka K, Tanaka M, Igarashi S, Onodera O, Miyatake T, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody II: passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg . 1995; 97 101-105
- 15 Graus F, Illa I, Agusti M. et al . Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci . 1991; 106 82-87
- 16 Sillevis Smitt A P, Manley G T, Posner J B. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology . 1995; 45 1873-1878
- 17 Levin M C, Lee S M, Kalume F. et al . Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med . 2002; 8 509-513
- 18 Henson R A, Hoffman H L, Urich H. Encephalomyelitis with carcinoma. Brain . 1965; 88 449-464
- 19 Graus F, Ribalta T, Campo E. et al . Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. Neurology . 1990; 40 219-222
- 20 Jean W C, Dalmau J, Ho A, Posner J B. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology . 1994; 44 140-147
- 21 Benyahia B, Liblau R, Merle-Béral H, Tourani J M, Dalmau J, Delattre J-Y. Cell-mediated auto-immunity in paraneoplastic neurologic syndromes with anti-Hu antibodies. Ann Neurol . 1999; 45 162-167
- 22 Albert M L, Austin L M, Darnell R B. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol . 2000; 47 9-17
- 23 Molinuevo J L, Graus F, Rene R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol . 1998; 44 976-980
- 24 Antoine J C, Honnorat J, Camdessanche J P. et al . Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol . 2001; 49 214-221
- 25 Dalmau J, Furneaux H M, Gralla R J, Kris M G, Posner J B. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer: a quantitative western blot analysis. Ann Neurol . 1990; 27 544-552
- 26 Vega F, Graus F, Chen Q M, Poisson M, Schuller E, Delattre J Y. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlation. Neurology . 1994; 44 2145-2147
- 27 Antoine J C, Cinotti L, Tilikete C. et al . [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol . 2000; 48 105-108
- 28 Rees J H, Hain S F, Johnson M R. et al . The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain . 2001; 124 2223-2231
- 29 Gultekin S H, Rosenfeld M R, Voltz R, Eichen J, Posner J B, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain . 2000; 123 1481-1494
- 30 Rosenfeld M R, Eichen J G, Wade D F, Posner J B, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol . 2001; 50 339-348
- 31 Dalmau J, Graus F, Rosenblum M K, Posner J B. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine . 1992; 71 59-72
- 32 Honnorat J, Antoine J C, Derrington E, Aguera M, Belin M F. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry . 1996; 61 270-278
- 33 Yu Z, Kryzer T J, Griesmann G E, Kim K-K, Benarroch E E, Lennon V A. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol . 2001; 49 146-154
- 34 Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre J Y. Limbic encephalitis and small cell lung cancer: clinical and immunological features. Brain . 1997; 120 923-928
- 35 Keime-Guibert F, Graus F, Broet P. et al . Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology . 1999; 53 1719-1723
- 36 Graus F, Keime-Guibert F, Rene R. et al . Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain . 2001; 124 1138-1148
- 37 Wainwright M S, Martin P L, Morse R P. et al . Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol . 2001; 50 612-619
- 38 Peterson K, Rosenblum M K, Kotanides H, Posner J B. Paraneoplastic cerebellar degeneration I: a clinical analysis of 55 anti-Yo antibody-positive patients. Neurology . 1992; 42 1931-1937
- 39 Graus F, Dalmau J, Valldeoriola F. et al . Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol . 1997; 74 55-61
- 40 Blaes F, Strittmatter M, Merkelbach S. et al . Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol . 1999; 246 299-303
- 41 Stark E, Wurster U, Patzold U, Sailer M, Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol . 1995; 52 814-818
- 42 David Y B, Warner E, Levitan M, Sutton D M, Malkin M G, Dalmau J O. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin: a case report. Cancer . 1996; 78 2153-2156
- 43 Cocconi G, Ceci G, Juvarra G. Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis: a case report. Cancer . 1985; 56 2318-2320
- 44 Paone J F, Jeyasingham K. Remission of cerebellar dysfunction after pneumonectomy for bronchogenic carcinoma. N Engl J Med . 1980; 302 156
- 45 Counsell C E, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology . 1994; 44 1184-1185
- 46 de la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol . 1998; 55 405-408
- 47 Keime-Guibert F, Graus F, Fleury A. et al . Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry . 2000; 68 479-482
- 48 Graus F, Vega F, Delattre J Y. et al . Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology . 1992; 42 536-540
- 49 Uchuya M, Graus F, Vega F, Reñé R, Delattre J Y. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry . 1996; 60 388-392
- 50 Russo C, Cohn S L, Petruzzi M J, de Alarcon A P. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol . 1997; 28 284-288
- 51 Yiu V W, Kovithavongs T, McGonigle L F, Ferreira P. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol . 2001; 24 72-74
- 52 Hammer M S, Larsen M B, Stack C V. Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol . 1995; 13 21-24
- 53 Mitchell W G, Snodgrass S R. Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome. J Child Neurol . 1990; 5 153-158
- 54 Koh P S, Raffensperger J G, Berry S. et al . Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr . 1994; 125 712-716
- 55 Anderson N E, Budde-Steffen C, Rosenblum M K. et al . Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine . 1988; 67 100-109
- 56 Luque F A, Furneaux H M, Ferziger R. et al . Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol . 1991; 29 241-251
- 57 Bataller L, Graus F, Saiz A, Vilchez J. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain . 2001; 124 437-443
- 58 Dropcho E J, Kline L B, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology . 1993; 43 207-211
- 59 Cher L M, Hochberg F H, Teruya J. et al . Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer . 1995; 75 1678-1683
- 60 Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med . 1990; 322 1555-1560
- 61 Folli F, Solimena M, Cofiell R. et al . Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med . 1993; 328 546-551
- 62 De Camilli P, Thomas A, Cofiell R. et al . The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med . 1993; 178 2219-2223
- 63 Butler M H, Hayashi A, Ohkoshi N. et al . Autoimmunity to gephyrin in stiff-man syndrome. Neuron . 2000; 26 307-312
- 64 Antoine J C, Absi L, Honnorat J. et al . Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol . 1999; 56 172-177
- 65 Schmierer K, Valdueza J M, Bender A. et al . Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression. Neurology . 1998; 51 250-252
- 66 Dalakas M C, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med . 2001; 345 1870-1876
- 67 Chalk C H, Windebank A J, Kimmel D W, McManis P G. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci . 1992; 19 346-351
- 68 Camdessanche J P, Antoine J C, Honnorat J. et al . Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiological study of 20 patients. Brain . 2002; 125 166-175
- 69 Oh S J, Dropcho E J, Claussen G C. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve . 1997; 20 1576-1582
- 70 Oh S J. Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin . 1997; 15 849-863
- 71 Antoine J C, Mosnier J F, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry . 1999; 67 7-14
- 72 Tim R W, Massey J M, Sanders D B. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology . 2000; 54 2176-2178
- 73 O'Neill J H, Murray N M, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain . 1988; 111 577-596
- 74 Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology . 2001; 57 1579-1582
- 75 Hart I K, Maddison P, Newsom-Davis J, Vincent A, Mills K R. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain . 2002; 125 1887-1895